English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
“We’ve identified, in a novel way, how abnormal cell metabolism impacts DNA repair,” said Peter Glazer, M.D., Ph.D., chair of the Department of Therapeutic Radiology at Yale and Chief of Radiation Oncology at Smilow Cancer Hospital. In earlier research, scientists in Glazer’s laboratory identified opportunities to treat cancers triggered by oncometabolites with an existing class of drugs called PARP (poly ADP-ribose polymerase) inhibitors. These drugs are designed to kill cancer by entirely shutting down an important DNA repair process in cells. Several PARP inhibitors are approved for treating breast and ovarian cancers with BRCA mutations.
Several early clinical studies are testing PARP inhibitors against glioma and other cancers driven by mutations in a gene known as IDH (isocitrate dehydrogenase 1) that churn out huge amounts of a metabolite called 2HG. These trials are spearheaded by Ranjit Bindra, M.D., Ph.D., associate professor of therapeutic radiology at Yale.
“The question still remained as to why these oncometabolites caused a DNA repair defect and create a vulnerability to PARP inhibitors?” said Glazer. “Our latest paper answers that question, diving into how abnormal metabolism walks over to a seemingly unrelated area of the cell to impact DNA repair.”
To uncover the details on the mechanism that goes wrong, the Yale scientists examined how oncometabolites affect DNA repair signaling in dozens of types of human cancer cells.
Within cells, DNA is wrapped around proteins called histones in a package called chromatin, which opens for the DNA to do its work, Glazer explained. When the DNA is damaged in a given location, histones are tagged with “methyl group” molecules that give a signal to start DNA repair.
“Our fundamental finding was that these metabolites inhibit an enzyme called KDM4B that regulates the presence of methyl groups on the histones,” said Glazer. “The consequence is that there are way too many methyl groups on the histones. That floods the system, so that the damage is masked.”
The Yale investigators now seek to more fully understand how oncometabolites can instigate or drive tumors, how PARP inhibitors can attack these tumors, and how resistance to the inhibitors can build up over time in cancer patients.
Parker Sulkowski, Ph.D., now at Dana-Farber Cancer Institute, is lead author on the paper. Bindra is co-corresponding author. Other Yale contributors include Sebastian Oeck, Jonathan Dow, Nicholas Economos, Lily Mirfakhraie, Yanfeng Liu, Katelyn Noronha and Megan King.
Lead funding for the study is from the National Institutes of Health and the American Cancer Society.
About Yale Cancer Center and Smilow Cancer Hospital Yale Cancer Center (YCC) is one of only 51 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Smilow Cancer Hospital is accredited by the Commission on Cancer, a Quality program of the American College of Surgeons. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
# # #
Original post https://alertarticles.info
